(SXTP) 60 Degrees Pharmaceuticals, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(SXTP) 60 Degrees Pharmaceuticals, Inc. Complete Analysis Pack
60 Degrees Pharmaceuticals: Business Model Canvas at a Glance
Unlock the full strategic blueprint behind 60 Degrees Pharmaceuticals, Inc.’s business model. This concise Business Model Canvas reveals how the company creates value, reaches customers, and builds its competitive edge in a specialized market. Perfect for investors, analysts, and founders who want actionable insight—download the full version to go deeper.
Partnerships
Tufts Medical Center license
60 Degrees Pharmaceuticals, Inc. has a patent license agreement with Tufts Medical Center that supports tafenoquine development for babesiosis, making it the company’s clearest named research and IP partnership. This link matters because babesiosis remains a niche, unmet-need market, so the license helps protect a focused clinical path for a repurposed anti-infective asset.
Clinical trial investigators
Clinical trial investigators are the physicians and study teams running 60 Degrees Pharmaceuticals, Inc.'s Phase IIb and Phase IIA tafenoquine trials. These sites handle enrollment, dosing, and data collection, and they are central to moving the program’s investigational uses forward; 60 Degrees Pharmaceuticals, Inc. relies on them to generate the safety and efficacy data that support each study readout.
CRO and data services
60 Degrees Pharmaceuticals, Inc. uses CRO and data services to run protocol execution, site monitoring, biostatistics, and study reports, which is vital for infectious-disease trials. With 1 approved drug, ARAKODA, and multiple pipeline programs to advance, these partners help the Company manage several studies at once without adding heavy in-house headcount.
Manufacturing and supply partners
60 Degrees Pharmaceuticals, Inc. depends on outside manufacturing and clinical-supply partners to make Arakoda and trial material, which is common for specialty pharma and helps protect continuity and scale-up. This setup lowers single-site risk and lets Company Name flex capacity without building its own plants.
- Contract makers for Arakoda
- GMP clinical-trial supply partners
- Backup capacity for continuity
- Scale-up support without heavy capex
Commercial distribution partners
Commercial distribution partners — wholesalers, specialty pharmacies, and channel distributors — are critical for 60 Degrees Pharmaceuticals, Inc. because Arakoda is an approved medicine and still needs a physical U.S. supply chain to reach prescribers and patients.
These partners expand access, support order fulfillment, and help convert prescriptions into delivered therapy; for an FDA-approved product, that last-mile reach can matter more than the label itself.
- Wholesalers stock and move product.
- Specialty pharmacies serve patients directly.
- Channel distributors widen U.S. access.
60 Degrees’ Lean Pharma Model Runs on Key External Partners
60 Degrees Pharmaceuticals, Inc. depends on Tufts Medical Center for tafenoquine IP, trial investigators for Phase IIb and Phase IIA execution, CROs for monitoring and biostatistics, and outside manufacturers plus distributors for Arakoda supply and U.S. reach. This partner mix lets the Company run a small specialty-pharma model without owning heavy infrastructure.
| Partner | Role |
|---|---|
| Tufts Medical Center | Patent license |
| Clinical sites | Trial execution |
| CROs | Monitoring, stats |
| Manufacturers | Drug and supply |
| Distributors | U.S. access |
What is included in the product
Detailed Word Document
A concise Business Model Canvas of 60 Degrees Pharmaceuticals, Inc. covering its drug development, partnerships, customers, channels, and revenue strategy.
Customizable Excel Spreadsheet
Simplifies 60 Degrees Pharmaceuticals’ business model into a clear one-page view, making pain points easy to spot and address.
Reference Sources
Provides a clear source trail that boosts credibility and helps investors verify key 60 Degrees Pharmaceuticals assumptions fast.
Activities
Arakoda commercialization
Arakoda commercialization is 60 Degrees Pharmaceuticals, Inc.’s core revenue activity: sale and support of its only approved product, Arakoda (tafenoquine) 100 mg, for malaria prophylaxis in adults. The work centers on market access, inventory supply, and prescribing support, since a single marketed asset means every prescription and refill matters.
Tafenoquine clinical development
60 Degrees Pharmaceuticals, Inc. is advancing tafenoquine through Phase IIb and Phase IIA studies, making this its core pipeline activity. The program spans COVID-19, babesiosis, fungal pneumonias, and candidiasis, with 4 active disease areas under clinical review.
Celgosivir development
60 Degrees Pharmaceuticals, Inc. is advancing celgosivir across 3 antiviral fronts: Zika, respiratory viruses, and dengue fever. That broadens the pipeline beyond tafenoquine and makes celgosivir a key future value driver, especially if later-stage data can convert its cross-virus activity into partnerable clinical programs.
Regulatory and safety work
60 Degrees Pharmaceuticals, Inc. must run FDA-facing development, safety monitoring, and compliance work, including IND/NDA filings, protocol updates, and 15-day serious adverse event reporting. For infectious disease drugs, strong pharmacovigilance is critical because post-approval use still needs tight tracking of rare risks and label adherence.
- FDA filings and trial updates
- Safety follow-up and AE reporting
- Post-market risk monitoring
IP and licensing management
60 Degrees Pharmaceuticals, Inc. treats IP and licensing as a core asset: it manages patents, licenses, and research collaborations to protect tafenoquine and extend its commercial life. The Tufts Medical Center agreement is a key example of how it uses external science to support label expansion and new uses, while keeping control of rights that drive future value.
Protect tafenoquine patent and license rights
Use Tufts Medical Center collaboration
Extend exclusivity with new indications
60 Degrees' 7-Area Pipeline Fuels Arakoda Growth
60 Degrees Pharmaceuticals, Inc. Key Activities are Arakoda commercialization, with market access and supply for its only approved product, plus tafenoquine and celgosivir R&D across 7 active disease areas. It also runs FDA filings, safety reporting, and IP/licensing work to extend exclusivity and support label growth.
| Key Activity | Data |
|---|---|
| Active areas | 7 |
| Approved product | Arakoda |
| Pipeline programs | 2 drugs |
Full Version Awaits
Business Model Canvas
The 60 Degrees Pharmaceuticals, Inc. Business Model Canvas preview you see here is the exact same document you’ll receive after purchase. It’s not a sample or mockup—just a direct view of the final file. Once your order is complete, you’ll download the same professionally formatted document, ready to use, edit, or present.
Resources
Arakoda approval
Arakoda, approved by the U.S. FDA in 2019 for malaria prophylaxis, is 60 Degrees Pharmaceuticals, Inc.’s only named marketed medicine and its core commercial asset. It gives the company a real sales base and a clear product identity in a niche travel-medicine market.
Tafenoquine asset
The tafenoquine asset is 60 Degrees Pharmaceuticals, Inc.'s main development resource, anchored by an FDA-approved malaria prophylaxis product and expanded through studies in multiple indications and formulations. That platform supports several future uses, including broader anti-malarial and potential repurposing programs, so one core asset can feed more than one pipeline path.
Celgosivir pipeline
Celgosivir is 60 Degrees Pharmaceuticals, Inc.'s second named investigational candidate, built to target viral diseases including Zika, respiratory viruses, and dengue. That broadens the Company's antiviral technical platform and adds a second development path beyond its lead asset.
Tufts license rights
Tufts license rights are a non-physical but critical resource for 60 Degrees Pharmaceuticals, Inc., giving access to licensed intellectual property used in babesiosis development. Those rights support the tafenoquine franchise and help defend the Company Name’s pipeline position around its core antimalarial and anti-parasitic assets.
- Licensed IP for babesiosis work
- Supports tafenoquine expansion
- Critical, non-physical asset
Infectious disease expertise
60 Degrees Pharmaceuticals, Inc. relies on a small, disease-focused team built around malaria and other infectious-disease know-how, which supports drug selection, development, and U.S. commercialization. The company’s lead FDA-approved product, ARAKODA, shows this expertise turns into real regulatory and market execution.
- Infectious-disease focus drives product choice
- Supports clinical and regulatory execution
- Backs U.S. commercialization of ARAKODA
Key Assets Driving 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals, Inc.’s key resources are its FDA-approved Arakoda tafenoquine asset, its Celgosivir antiviral program, and its Tufts-licensed babesiosis IP. The Company also relies on a small infectious-disease team that supports development and U.S. commercialization.
| Resource | Why it matters |
|---|---|
| Arakoda | FDA approved in 2019 |
| Tufts IP | Babesiosis rights |
| Celgosivir | Second pipeline asset |
Value Propositions
Approved malaria prophylaxis
Arakoda, 60 Degrees Pharmaceuticals, Inc.'s FDA-approved malaria prophylaxis, gives prescribers a ready-use prevention option and lowers development risk versus an experimental asset. WHO estimated 263 million malaria cases and 597,000 deaths in 83 countries in 2023, underscoring the need for approved prevention.
Multi-indication antifectives
60 Degrees Pharmaceuticals, Inc. uses 2 lead assets, tafenoquine and celgosivir, to target several infectious diseases at once: malaria, parasitic, fungal, and viral. That breadth matters in markets with huge unmet need, including 263 million malaria cases and 6.5 million dengue cases reported globally in 2023, giving the Company multiple shots on goal.
Repurposed tafenoquine
Tafenoquine gives 60 Degrees Pharmaceuticals one asset that can be reused across several diseases, with Phase IIb and Phase IIA studies already under way for multiple indications. That repurposing path can cut development time and cost versus starting from zero, while extending the same molecule’s commercial runway.
Need for U.S. infectious disease options
60 Degrees Pharmaceuticals, Inc. targets U.S. prevention and treatment gaps in infectious disease, led by ARAKODA for malaria prophylaxis in adults. This matters in a niche where the U.S. sees about 2,000 malaria cases a year, mostly travel-related, while CDC says antimicrobial resistance drives more than 2.8 million infections and 35,000 deaths annually.
- Focuses on U.S. prevention and treatment
- Serves diseases with few specialist options
- Targets a high-need, low-competition niche
Specialty pharma focus
60 Degrees Pharmaceuticals keeps a narrow, disease-specific model: it focuses on infectious diseases, led by malaria, instead of building a broad pharma platform. That focus supports tighter R&D and commercialization around one FDA-approved product, ARAKODA, in a market where malaria still caused about 249 million cases worldwide in 2022.
- One disease-led portfolio
- FDA-approved anti-malarial focus
- Targeted development and sales
FDA-Approved Malaria Defense With Repurposing Upside
60 Degrees Pharmaceuticals, Inc. offers a rare FDA-approved malaria prophylaxis with ARAKODA, plus a repurposing-led pipeline that can reuse tafenoquine across multiple infectious diseases. That mix lowers development risk and gives prescribers one ready option in a market where WHO counted 263 million malaria cases and 597,000 deaths in 2023.
| Value driver | Data point |
|---|---|
| Lead asset | ARAKODA |
| Global malaria burden | 263 million cases, 597,000 deaths |
Customer Relationships
Physician-prescriber support
60 Degrees Pharmaceuticals, Inc. must build physician-prescriber support around clinical evidence, dosing guidance, and patient selection, because prescription use depends on doctors choosing the right treatment for the right case. That matters especially in malaria care, where U.S. cases are still measured in the low thousands each year and prescriber confidence drives real uptake.
Medical affairs engagement
60 Degrees Pharmaceuticals uses medical affairs to share peer-level science with infectious disease specialists, focusing on clinical data, dosing, and safety for ARAKODA, its FDA-approved tafenoquine product for malaria prevention. This evidence-led dialogue turns trial and label data into prescribing, and the 6-dose regimen is a key part of that message.
Research collaboration model
60 Degrees Pharmaceuticals, Inc. uses a joint research model with Tufts Medical Center and trial sites, sharing protocol design, clinical oversight, and data review. In early- and mid-stage infectious disease development, this kind of collaboration speeds recruitment and builds credibility through direct access to specialist expertise.
Patient access support
Patient access support helps patients obtain approved treatment through the commercial channel, which matters most for specialty medicines like Arakoda, where pharmacy routing, prior approval, and distribution steps can slow start time. For 60 Degrees Pharmaceuticals, Inc., this support can improve fill rates and reduce drop-off at the point of access.
- Guides commercial-channel access
- Supports specialty pharmacy steps
- Helps patients start Arakoda faster
Clinical trial participant relationship
60 Degrees Pharmaceuticals, Inc. keeps clinical trial participants under tight consent, follow-up, and monitoring protocols so each study visit yields usable safety and efficacy data. That matters in pipeline work like tafenoquine and celgosivir, where structured participation and repeated data capture support endpoint quality and regulatory-grade evidence.
- Informed consent before dosing
- Scheduled follow-up visits
- Ongoing safety monitoring
- Repeated data collection
How 60 Degrees Pharma Builds Trust to Speed ARAKODA Access
60 Degrees Pharmaceuticals, Inc. builds customer relationships through physician education, specialty pharmacy access, and trial-site collaboration, so trust is created before and after prescribing. For ARAKODA, the main goal is simple: help the right patients get the right malaria-prevention treatment fast.
| Channel | Role |
|---|---|
| Physicians | Evidence-led prescribing |
| Specialty pharmacy | Access and fulfillment |
| Trial sites | Consent, follow-up, safety |
Channels
Physician prescribing
Physician prescribing is the main route for Arakoda use, since it is a prescription-only antimalarial and clinicians decide on prophylaxis before travel. This channel matters because approved medicines reach patients through doctors and travel clinics, making prescriber access the core commercial path for 60 Degrees Pharmaceuticals, Inc.
Specialty pharmacies
Specialty pharmacies are the main pharmacy route for 60 Degrees Pharmaceuticals, Inc.’s infectious-disease products, because they help with access, prior auth, and refill support for niche drugs like Arakoda (tafenoquine) for malaria prevention. They also improve adherence through counseling and shipment tracking, which matters for a weekly prophylaxis regimen.
Wholesaler distribution
60 Degrees Pharmaceuticals, Inc. uses U.S. wholesalers as the main upstream path into pharmacies and hospitals, which helps keep stock available and reduces gaps in inventory flow. This channel fits prescription drug distribution, where wholesalers consolidate supply, place purchase orders, and speed access across the market.
Clinical trial sites
60 Degrees Pharmaceuticals uses clinical trial sites as the main channel for investigational products, with tafenoquine and celgosivir both needing formal study settings. These sites are the core path for pipeline advancement, and the latest public filing did not disclose a current site count.
- Formal trial sites for tafenoquine
- Formal trial sites for celgosivir
- Main channel for pipeline progress
Scientific and medical outreach
Scientific and medical outreach uses conferences, publications, and medical communications to build evidence-based awareness for specialty pharma. With malaria still causing 263 million cases and 597,000 deaths worldwide in 2023, this channel helps 60 Degrees Pharmaceuticals, Inc. earn trust with clinicians and researchers through clear, data-led education.
- Conferences: peer access
- Publications: clinical proof
- Medical comms: trust and adoption
Arakoda’s Go-to-Market: Physicians, Pharmacies, and Wholesalers
60 Degrees Pharmaceuticals, Inc. sells Arakoda mainly through physician prescribing, specialty pharmacies, and U.S. wholesalers, with clinical trial sites used for tafenoquine and celgosivir studies. Scientific outreach via conferences and publications supports clinician trust in a market where malaria caused 263 million cases and 597,000 deaths in 2023.
| Channel | Role |
|---|---|
| Physicians | Prescribe Arakoda |
| Specialty pharmacies | Access and refill support |
| Wholesalers | Supply pharmacies |
Customer Segments
Malaria prophylaxis patients
Malaria prophylaxis patients are travelers and other U.S. adults who need prevention before trips to malaria-risk regions. Arakoda directly serves this group, and it is Company Name’s clearest commercial patient segment.
Infectious disease physicians
Infectious disease physicians diagnose and treat hard-to-manage infections, so they strongly shape prescribing for 60 Degrees Pharmaceuticals, Inc. products and help drive trial enrollment. They are key decision-makers because they can weigh safety, resistance risk, and clinical need when choosing therapies for complex patients.
Travel medicine clinics
Travel medicine clinics are a natural point of access for Arakoda because they prescribe malaria prevention before trips and can match prophylaxis to destination risk, duration, and patient history. With malaria causing about 249 million cases and 608,000 deaths globally in 2022, these clinics also support education on risk-based prophylaxis and preventive adherence.
Clinical trial populations
60 Degrees Pharmaceuticals, Inc. focuses on clinical trial populations with COVID-19, babesiosis, fungal pneumonias, candidiasis, Zika, respiratory viruses, and dengue. These groups are not commercial customers today, but they are the core test base for pipeline work; dengue alone still causes about 100 to 400 million infections a year worldwide.
- Pipeline-ready study participants
- Used to test safety and efficacy
- Not buyers, but key development users
Hospitals and specialty care settings
Hospitals, specialty clinics, and care networks are core customers for 60 Degrees Pharmaceuticals, Inc. because they treat infectious disease cases and run trial sites. In the U.S., there are about 6,000 hospitals, and these groups also shape formulary and access decisions that drive adoption.
- Infectious disease treatment
- Clinical trial execution
- Formulary access control
60 Degrees Pharma: Travelers, Clinicians, and Malaria Access
60 Degrees Pharmaceuticals, Inc. serves two main customer groups: malaria prophylaxis patients, mainly U.S. travelers, and the clinicians who steer access, including infectious disease physicians and travel medicine clinics. Its pipeline also depends on trial-site patients and hospitals, where infectious disease care and enrollment decisions shape development.
| Segment | Role | Key data |
|---|---|---|
| Travelers | Arakoda users | Malaria caused 249M cases in 2022 |
| Clinicians | Prescribers | Guide safety and access |
Cost Structure
Clinical trial spend
Clinical trial spend is the biggest growth cost for 60 Degrees Pharmaceuticals, Inc., especially in Phase IIA and Phase IIb work, where enrollment, site monitoring, bioanalysis, and FDA-ready reporting drive most of the bill. Industry data put Phase II programs in the roughly $7 million to $20 million range per study, and a single Phase IIb can run higher when endpoints are hard to recruit.
Manufacturing costs
Manufacturing costs include production for Arakoda and investigational clinical material, so 60 Degrees Pharmaceuticals, Inc. carries spend on both commercial supply and trial batches. In fiscal 2025, small-scale runs and quality control likely kept unit costs high, because fixed testing and batch-release work do not fall much with low volume.
Regulatory compliance
Regulatory compliance is a fixed, ongoing cost for 60 Degrees Pharmaceuticals, Inc., covering FDA filings, quality control, and safety monitoring. Clinical development and post-market oversight also need validated systems for adverse-event tracking, audits, and documentation, so these costs keep running after launch.
Sales and marketing
Sales and marketing for Arakoda centers on physician education, specialty-channel support, and commercial promotion, because malaria prevention is still a narrow, prescription-driven market. This cost rises as 60 Degrees Pharmaceuticals, Inc. pushes into more prescribers, travel clinics, and pharmacy channels.
- Physician education drives Arakoda demand
- Specialty channels need active support
- Reach expansion lifts selling costs
IP and licensing fees
IP and licensing fees stay a real fixed cost for 60 Degrees Pharmaceuticals, Inc. because tafenoquine is protected by patents and a Tufts Medical Center license that needs ongoing legal, patent, and maintenance work. That spend can be small in cash terms, but it is mandatory to keep rights alive and defend exclusivity.
- Patent prosecution and renewals
- License maintenance and royalties
- Legal defense of tafenoquine rights
60 Degrees’ Biggest Cost: Clinical Trials and Compliance
60 Degrees Pharmaceuticals, Inc. cost structure is dominated by R&D: Phase IIA/IIb trials, FDA-grade regulatory work, and low-volume manufacturing for Arakoda and trial batches. Phase II programs often cost $7M-$20M per study, so clinical spend stays the main cash drain.
| Cost item | Latest data |
|---|---|
| Phase II trials | $7M-$20M+ |
| Commercial supply | Low-volume, high unit cost |
| Compliance | Ongoing fixed spend |
Revenue Streams
Arakoda product sales
Arakoda product sales are 60 Degrees Pharmaceuticals, Inc.'s only clearly marketed revenue stream and come from its FDA-approved malaria prophylaxis tablet, Arakoda. In 2025, this remained the company’s core commercial line, with sales tied to travel medicine demand and prescription uptake.
Future tafenoquine sales
Future tafenoquine sales could expand beyond the current malaria franchise if new uses win approval. With Phase IIb and Phase IIA studies in two programs, 60 Degrees Pharmaceuticals, Inc. has a pipeline-based revenue upside that could turn one drug into multiple commercial products.
Future celgosivir sales
If celgosivir wins approval, 60 Degrees Pharmaceuticals, Inc. could add product sales from more than one viral disease, since the candidate has been studied as a broad-spectrum antiviral. Each approved indication could open a separate revenue stream, with demand shaped by disease incidence, pricing, and any future label size.
License-derived income
License-derived income can add value to 60 Degrees Pharmaceuticals, Inc. beyond direct drug sales by monetizing intellectual property rights and collaboration deals. The Tufts Medical Center agreement shows the Company can work through licensed assets, so royalties, milestone payments, or partner-funded research can support revenue even when product sales are uneven.
- IP can generate royalties and milestones.
- Tufts deal proves licensed-asset execution.
- Income can scale beyond product sales.
Broader infectious disease portfolio
60 Degrees Pharmaceuticals, Inc. can build long-term revenue by expanding tafenoquine into multiple prevention and treatment uses, which lowers reliance on one indication and supports a diversified specialty pharma model. The company’s latest public filings show a narrow current base, so each added infectious-disease label can widen sales and de-risk cash flow over time.
- Multiple indications can extend product life.
- One pipeline lowers single-product risk.
- Diversified uses support steadier revenue.
Arakoda Drives Revenue, with Pipeline and Licensing Fueling Growth
60 Degrees Pharmaceuticals, Inc. has one clear current revenue stream: Arakoda product sales, driven by its FDA-approved malaria prophylaxis tablet. Growth upside comes from future tafenoquine labels, celgosivir approvals, and license income such as royalties or milestones from partnered assets.
| Stream | 2025/2026 status |
|---|---|
| Arakoda sales | Core revenue |
| Tafenoquine pipeline | 2 studies active |
| Licensing | Royalties/milestones |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.